Transgene TRGNF Stock
Transgene Price Chart
Transgene TRGNF Financial and Trading Overview
| Transgene stock price | 0.8 USD |
| Previous Close | 0.8 USD |
| Open | 0.8 USD |
| Bid | 0.55 USD x 100000 |
| Ask | 0 USD x 100000 |
| Day's Range | 0.8 - 0.8 USD |
| 52 Week Range | 0.7 - 1.08 USD |
| Volume | 1K USD |
| Avg. Volume | 17 USD |
| Market Cap | 222.6M USD |
| Beta (5Y Monthly) | 0.723 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
TRGNF Valuation Measures
| Enterprise Value | 128.84M USD |
| Trailing P/E | N/A |
| Forward P/E | -0.9756098 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 39.581146 |
| Price/Book (mrq) | 1.7892241 |
| Enterprise Value/Revenue | 22.908 |
| Enterprise Value/EBITDA | -3.857 |
Trading Information
Transgene Stock Price History
| Beta (5Y Monthly) | 0.723 |
| 52-Week Change | 14.28% |
| S&P500 52-Week Change | 12.83% |
| 52 Week High | 1.08 USD |
| 52 Week Low | 0.7 USD |
| 50-Day Moving Average | 0.8 USD |
| 200-Day Moving Average | 0.89 USD |
TRGNF Share Statistics
| Avg. Volume (3 month) | 17 USD |
| Avg. Daily Volume (10-Days) | 100 USD |
| Shares Outstanding | 278.26M |
| Float | 48.96M |
| Short Ratio | N/A |
| % Held by Insiders | 80.77% |
| % Held by Institutions | 0% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -559.30% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -26.23% |
| Return on Equity (ttm) | -64.20% |
Income Statement
| Revenue (ttm) | 5.62M USD |
| Revenue Per Share (ttm) | 0.03 USD |
| Quarterly Revenue Growth (yoy) | -34.59% |
| Gross Profit (ttm) | -25787000 USD |
| EBITDA | -33401000 USD |
| Net Income Avi to Common (ttm) | -33898000 USD |
| Diluted EPS (ttm) | -0.2 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 92.84M USD |
| Total Cash Per Share (mrq) | 0.34 USD |
| Total Debt (mrq) | 2.18M USD |
| Total Debt/Equity (mrq) | 2 USD |
| Current Ratio (mrq) | 9.4 |
| Book Value Per Share (mrq) | 0.44712117 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -38658000 USD |
| Levered Free Cash Flow (ttm) | -24369000 USD |
Profile of Transgene
| Country | United States |
| State | N/A |
| City | Illkirch-Graffenstaden |
| Address | 400, boulevard Gonthier d’Andernach |
| ZIP | 67405 |
| Phone | 33 3 88 27 91 00 |
| Website | https://www.transgene.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 152 |
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG6050 for the treatment of non-small cell lung cancer that is in Phase 1 clinical trial. It has strategic collaboration agreements with NEC Corporation and NEC Bio, BioInvent, Merck & Co., Inc., Oxford Biomedica, Stamford, SillaJen, and ProBioGen. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
Q&A For Transgene Stock
What is a current TRGNF stock price?
Transgene TRGNF stock price today per share is 0.8 USD.
How to purchase Transgene stock?
You can buy TRGNF shares on the OTC Markets EXMKT exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Transgene?
The stock symbol or ticker of Transgene is TRGNF.
Which industry does the Transgene company belong to?
The Transgene industry is Biotechnology.
How many shares does Transgene have in circulation?
The max supply of Transgene shares is 278.26M.
What is Transgene Price to Earnings Ratio (PE Ratio)?
Transgene PE Ratio is now.
What was Transgene earnings per share over the trailing 12 months (TTM)?
Transgene EPS is -0.2 USD over the trailing 12 months.
Which sector does the Transgene company belong to?
The Transgene sector is Healthcare.
